BXCL501 FDA Approval Status
FDA Approved: No
Brand name: BXCL501
Generic name: dexmedetomidine
Company: BioXcel Therapeutics, Inc.
Treatment for: Agitation
BXCL501 (dexmedetomidine) is an orally dissolving thin film formulation of the approved alpha2-adrenergic agonist dexmedetomidine in development for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.
Development Timeline for BXCL501
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.